This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains
by Zacks Equity Research
Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.
NVOPositive Net Change VNDAPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?
by Ekta Bagri
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
by Ekta Bagri
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change AMGNPositive Net Change
biotechnology biotechs dividend-yield medical pharmaceuticals
Can Amgen's MariTide Take on Leaders in the Obesity Space?
by Zacks Equity Research
AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.
RAREPositive Net Change CRMDPositive Net Change MREOPositive Net Change CSTLPositive Net Change
biotechs
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains
by Sundeep Ganoria
Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.
JNJPositive Net Change MRKPositive Net Change ABBVPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals vaccines
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
by Zacks Equity Research
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
ANIPPositive Net Change CRMDPositive Net Change CSTLPositive Net Change KYTXPositive Net Change
biotechs
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
by Sundeep Ganoria
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
ALTPositive Net Change MCRBPositive Net Change IBRXPositive Net Change
biotechs medical
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
by Zacks Equity Research
Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.
ANIPPositive Net Change CRMDPositive Net Change CSTLPositive Net Change OCGNPositive Net Change
biotechs
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
by Zacks Equity Research
MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
ANIPPositive Net Change CRMDPositive Net Change CSTLPositive Net Change MNMDPositive Net Change
biotechs
3 Biotech Stocks With Major 2026 Catalysts
by Ekta Bagri
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
VNDAPositive Net Change DNLIPositive Net Change NUVLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
by Kanishka Das
CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechs
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label
by Zacks Equity Research
Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.
AGIOPositive Net Change ANIPPositive Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechs
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
by Kanishka Das
MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
NKTRPositive Net Change INSMPositive Net Change LYELPositive Net Change MLYSPositive Net Change
biotechs medical
Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know
by Sundeep Ganoria
AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.
GSKPositive Net Change BMYPositive Net Change MRKPositive Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
by Zacks Equity Research
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
SNYNegative Net Change DVAXNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
by Ekta Bagri
BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
by Sundeep Ganoria
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
AZNPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals vaccines
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
by Zacks Equity Research
NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
GILD Exercises Option to License Assembly Bio's Herpes Programs
by Zacks Equity Research
Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
GILDPositive Net Change CRMDPositive Net Change ASMBPositive Net Change CSTLPositive Net Change
biotechs
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies
by Zacks Equity Research
CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.
LLYPositive Net Change CRMDPositive Net Change CRSPPositive Net Change CSTLPositive Net Change
biotechs
JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
by Zacks Equity Research
Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.
JNJPositive Net Change ANIPPositive Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechs medical
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
by Ahan Chakraborty
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
5 Big Drug Stocks That May Continue to Outperform in 2026
by Kinjel Shah
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
AZNPositive Net Change JNJPositive Net Change LLYPositive Net Change AMGNPositive Net Change ABBVPositive Net Change
biotechs pharmaceuticals
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
by Zacks Equity Research
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
AZNPositive Net Change JNJPositive Net Change HALOPositive Net Change
biotechs medical pharmaceuticals